Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celebrex, Bextra Stabilizing After FDA Advisory Committee Review, Pfizer Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Company is predicting a return to growth in the COX-2 category once FDA completes work on new labeling. Celebrex and Bextra "will remain critical treatment options for many years to come," Pfizer tells analysts.

You may also be interested in...



Silver Lining For Pfizer? Celebrex Well-Positioned In NSAID Class

The boxed warning for Pfizer's Celebrex will differ only slightly from labeling for other prescription NSAIDs, FDA says. All products will bear new language addressing increased cardiovascular and gastrointestinal risks. The agency appears open to renewed direct-to-consumer advertising for Celebrex.

Celebrex Long-Term Safety Study Planned

Pfizer will work with FDA to design a long-term safety study for Celebrex following the agency's decision to recommend a "black box" warning on the COX-2 inhibitor's increased risk for cardiovascular events

FDA's COX-2 Safety Plan: Remove Bextra, Add "Black Box" To Celebrex

Pfizer has not yet agreed to withdraw Bextra but will suspend marketing pending further discussions with FDA. Boxed warning on all prescription NSAIDS – including Celebrex – will discuss increased cardiovascular and gastrointestinal risk. FDA's decision comes two days after Pfizer tells analysts COX-2 inhibitor sales are stabilizing.

Related Content

Topics

UsernamePublicRestriction

Register

PS062132

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel